SSR181507, a dopamine D2 receptor antagonist and 5-HT 1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit

Psychopharmacology

Volumn 181, Issue 1, 2005, Pages 134-144

  Terranova, J P ^a   Chabot, C ^a   Barnouin, M C ^a   Perrault, G ^a   Depoortere, R ^a   Griebel, G ^a   Scatton, B ^a  

^a SANOFI   (France)

Author keywords

5 HT1A agonist; Antipsychotic activity; D2 antagonist; Information processing; Novelty discrimination; Phencyclidine; Schizophrenia; Selective attention; SSR181507

Indexed keywords

AMISULPRIDE; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; PHENCYCLIDINE; SEROTONIN 1A AGONIST; SSR 181507; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DISCRIMINATION LEARNING; DISCRIMINATIVE STIMULUS; DRUG ACTIVITY; EXPLORATORY BEHAVIOR; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SELECTIVE ATTENTION; SOCIAL ENVIRONMENT;

AGE FACTORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; CLOZAPINE; DEXTROAMPHETAMINE; DIOXANES; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; IMIPRAMINE; INJECTIONS, INTRAPERITONEAL; MALE; PHENCYCLIDINE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; RECOGNITION (PSYCHOLOGY); SEROTONIN ANTAGONISTS; SOCIAL BEHAVIOR; TACRINE; TROPANES;

EID: 26444518328     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2268-5     Document Type: Article

References (51)

1. Addington J, Addington MD, Gasbarre L (1996) Distractibility and symptoms in schizophrenia. J Psychiatry Neurosci 22:180-184
2. Al-Amin HA, Weinberger DR, Lipska BK (2000) Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav Pharmacol 11:269-278
3. Bakker CB, Amini FB (1961) Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry 2:269-280
4. Barch DM, Carter CS, Hachten PC, Usher M, Cohen JD (1999) The "benefits" of distractibility: mechanism underlying increased Stroop effects in schizophrenia. Schizophr Bull 25:749-762
5. Black MD, Lister S, Hichcock JM, Van Giersgergen P, Soresen SM (1998) Neonatal hippocampal lesion model of schizophrenia in rats: sex differences and persistence of effects into maturity. Drug Dev Res 43:206-213
6. 1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46:1121-1129
7. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychopharmacology 15:339-343
8. Brébion G, Smith MJ, Gorman JM, Malaspina D, Sharif Z, Amador X (2000) Memory and schizophrenia: differential link of processing speed and selective attention with two levels of encoding. J Psychiatr Res 34:121-127
9. 1A. receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology 28:2064-2076
10. Cohen JD, Servan-Schreiber D (1992) Context, cortex and dopamine: a connectionist approach to behavior and biology in schizophrenia. Psychol Rev 99:45-77
11. Coward DM, Imperato A, Urwyler S, White TG (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology 99:6-12
12. Craft S, Gourovitch ML, Dowton SB, Swanson JM, Bonforte S (1992) Lateralized deficits in visual attention in males with developmental dopamine depletion. Neuropsychologia 30:341-351
13. 1A receptor agonist. II. Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28:1889-1902
14. Engelmann M, Wotjak CT, Landgraf R (1995) Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol Behav 58:315-321
15. Freedman R, Olincy A, Ross RG, Waldo MC, Stevens KE, Adler LE, Leonard S (2003) The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 5:155-161
16. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485-498
17. Geyer MA, Krebs-Thompson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating in schizophrenia: a decade in review. Psychopharmacology 156:117-154
18. Hofer E, Doby D, Anderer P, Dantendorfer K (2001) Impaired conditional discrimination learning in schizophrenia. Schizophr Res 51:127-136
19. Jackson JJ, Soliman MR (1996) Effects of tacrine (THA) on spatial reference memory and cholinergic enzymes in specific rat brain regions. Life Sci 58:47-54
20. Jin J, Yamamoto T, Watanabe S (1997) The involvement of sigma receptors in the choice reaction performance deficits induced by phencyclidine. Eur J Pharmacol 319:147-152
21. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
22. Lewis R (2004) Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiatry Neurosci 29:102-113
23. Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205-229
24. Lipska BK, Weinberger MD (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 233:223-239
25. Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67-75
26. Lipska BK, Chrapusta SJ, Egan MF, Weinberger DR (1995) Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse 20:125-130
27. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308
28. McKetin R, SoloWij N (1999) Event-related potential indices of auditory selective attention in dependent amphetamine users. Biol Psychiatry 45:1488-1497
29. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
30. Moser PC, Hitchcock JM, Lister S, Moran PM (2000) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33:275-307
31. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363:2063-2072
32. Muller TJ, Kalus P, Strik WK (2001) The neurophysiological meaning of auditory P300 in subtypes of schizophrenia. World J Biol Psychiatry 2:9-17
33. Oranje B, Van Berckel BN, Kemner C, Van Ree JM, Kahn RS, Verbaten MN (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22:293-302
34. Perio A, Terranova JP, Worms P, Bluthe RM, Dantzer R, Biziere K (1989) Specific modulation of social memory in rats by cholinomimetic and nootropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants. Psychopharmacology 97:262-268
35. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82
36. Pinelli P, Ceriani F, Colombo R, Pasetti C, Terazzi M, Castignoli G (2000) Delayed verbal reactions are specifically impaired in patients with schizophrenia. Int J Psychol 37:163-175
37. Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 165:362-380
38. Russig H, Kovacevic A, Murphy CA, Feldon J (2003) Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion. Psychopharmacology 170:263-270
39. Salo R, Nordahl TE, Possin K, Leamon M, Gibson DR, Galloway GP, Flynn NM, Henik A, Pfefferbaum A, Sullivan EV (2002) Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res 111:65-74
40. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
41. Servan-Schreiber D, Bruno RM, Carter CS, Cohen JD (1998) Dopamine and the mechanisms of cognition. Part I. A neural network model predicting dopamine effects on selective attention. Biol Psychiatry 43:713-722
42. Sharma T (1999) Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 38:44-51
43. Silverstein SM (1997) Information processing, social cognition, and psychiatric rehabilitation in schizophrenia. Psychiatry 60:327-340
44. Stemmelin J, Cassel JC, Will B, Kelche C (1999) Sensitivity to cholinergic drug treatment of aged rats with variable degrees of spatial memory impairment. Behav Brain Res 98:53-66
45. Swerdlow NR, Braff DL, Geyer MA (2000) Animals models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11:185-204
46. Turgeon SM, Auerbach EA, Heller MA (1998) The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol Biochem Behav 60:553-558
47. Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: a comparison with E2020 and tacrine. Eur J Pharmacol 349:137-142
48. Wang C, Mcinnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001) Long-term behavioural and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107:535-550
49. Wang C, McInnis J, West JB, Bao J, Anastasio N, Guidry JA, Ye Y, Salvemini D, Johnson KM (2003) Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J Pharmacol Exp Ther 304:266-272
50. Weiner I (2003) The "two-headed" latent inhibition model of schizophrenia: modelling positive and negative symptoms and their treatment. Psychopharmacology 169:257-297
51. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996) The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40:834-843